molecules 2

Our Mission

Our mission is to rapidly advance personalized drug discovery for rare genetic diseases. 

WHO WE ARE

At Modelis, we leverage advanced drug discovery methods to reduce the time and resources it takes to repurpose existing treatments for rare genetic diseases. Our innovative approach repurposes proprietary and known molecules from our partners for a wide range of human disorders.

Modelis’  is a high throughput solution to discovering new treatments for rare genetic diseases due to our research methodology that leverages patient genetic avatars and CRISPR. 

We leverage artificial intelligence/machine learning and academic collaborations through our partner network to identify new mechanisms of action and rapidly translate our animal model findings into human clinical trials.

OUR STORY

Modelis’ pipeline is based on ground-breaking research by Dr. Alex Parker (co-founder and Chief Scientific Officer at Modelis) and colleagues which led to the discovery of a new therapeutic compound for Amyotrophic Lateral Sclerosis (ALS).

In short, more than 4,000 approved compounds were tested against motor defects described in ALS-like mutant worms. Interestingly, several of these molecules belonging to the neuroleptic family were found to have a beneficial effect on these motor defects. A short list of fifteen of these neuroleptics were validated on ALS genetic avatars and Pimozide stood out as the more promising candidate. Pimozide is an Food and Drug Administration (FDA)- approved drug that was originally used to treat schizophrenia. Finally, electrophysiological studies in mouse models confirmed the beneficial effects of Pimozide when treating motor defects caused by ALS. Following these results, a proof-of-concept clinical trial was performed suggesting an apparent stabilization of motor power deterioration. A ten-centre randomized controlled clinical trial examining the effect of 6 months of pimozide therapy in patients with ALS is underway (ID NCT03272503) and is expected to be completed by the end 2020.

OUR EXPERT TEAM IS READY TO WORK WITH YOU

alex

Alex Parker, PhD

Chief Scientific Officer

Director of Research and Development

james

James Doyle, PhD

Chief Executive officer

President

Eric Samarut, PhD, MBA

Chief Financial officer

Director of Business Development

OUR ADVISORS ARE GUIDING MODELIS TO NEW HEIGHTS

New Project-4

Mark Starratt

CIM, ICD.D, FEA, AIF, BCOMM

Gordon Anderson

B. Admin., TEP, ICD.D, FEA, CFA

OUR ETHICS AND ANIMAL CARE

At Modelis, we want to make a difference and are translating this into value for patients. Our main goal is to make an impact in our patients journey and quality of life. We are less concerned about publishing in top research journals. 

integrity

Integrity

We are driven and focused on the individuals health. Our team of passionate scientists are deploying efforts toward this aim and all decisions are prioritizing public wellness. To reach its mission and vision, we rely on strong values: Passion, Expertise and Innovation.

transparency

Transparency

As a for-profit organization, we will remain transparent on our industrial partnerships and financial position.

animal care

Animal Care

Modelis’ research is reducing the use of animals in research, especially mammals. Moreover, our research is conducted in accordance to the Canadian Council on Animal Care to ensure ethical procedures.
social

Social Responsibility

Modelis is promoting local economies and is contributing to the rise of the thriving technological innovation culture in Montreal, Quebec, and all of Canada.

Learn more about our research

Our research is rapidly advancing drug discovery and bridging the gap between bench and bedside.

©2020 Modelis inc. All rights reserved